FDA approves Tecentriq after surgery for a type of stage 3 colon cancer
Published
Adding the immunotherapy to standard chemotherapy cut the risk of the cancer coming back or death by about half in a trial of patients with dMMR tumors. Ask your oncologist whether your tumor was tested for this marker.
Source: Targeted Oncology
This is a plain-language summary. Read the original source for full details.